43 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
unfavorable results;
patient recruitment and enrollment in clinical trials may be slower than we anticipate;
clinical trials may produce negative
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
22 May 23
Regulation FD Disclosure
7:00am
into nucleus and subsequent scanning of the genome for locus Precise engagement and recruitment of endogenous DNA repair machinery to install correction 1
424B5
NBSE
NeuBase Therapeutics Inc
29 Dec 22
Prospectus supplement for primary offering
5:03pm
and pharmacokinetics and optimize their formulation, among other things, may produce unfavorable results;
patient recruitment and enrollment in clinical trials
8-K
EX-99.1
90k3srb3a9o8c
14 Oct 22
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
4:20pm
424B5
7q8qdg67
27 Aug 21
Prospectus supplement for primary offering
5:21pm
424B5
50m3dcnu4102htajt7j
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
mwt9tcdu6cwwh5v
21 Apr 21
Prospectus supplement for primary offering
4:03pm
424B3
j7p7v8asid9x7584l
6 Jun 19
Prospectus supplement
5:15pm